Adult-onset Still’s disease: Current challenges and future prospects

Mariam Aysha Siddiqui, Michael S. Putman, Anisha Bharadwaj Dua*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Adult-onset Still’s disease (AOSD) - a multi-systemic inflammatory condition characterized by high fevers, polyarthritis, an evanescent rash, and pharyngitis - has been a challenging condition to diagnose expediently and treat effectively. Questions remain regarding the underlying pathophysiology and etiology of AOSD. Pathognomonic diagnostic tests and reliable biomarkers remain undiscovered. Over the past decade, important progress has been made. Diagnostic criteria employing glycosylated ferritin have improved specificity. More important, novel biologic therapies have offered important clues to AOSD’s underlying pathophysiology. Cytokine-specific biologic therapies have been instrumental in providing more effective treatment for disease refractory to conventional treatment. While IL-1 therapy has demonstrated efficacy in refractory disease, novel therapies targeting IL-6 and IL-18 show great promise and are currently under investigation.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalOpen Access Rheumatology: Research and Reviews
StatePublished - Mar 15 2016


  • Adult-onset still’s disease
  • Biomarkers
  • Therapeutics

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Adult-onset Still’s disease: Current challenges and future prospects'. Together they form a unique fingerprint.

Cite this